Elisabet Lindberg overview
Elisabet Lindberg obtained her medical degree from the Karolinska Institute in Stockholm, Sweden. She trained as a general surgeon at the Karolinska Hospital. In 1988 she joined Roche where she was responsible for clinical studies in cardiology, obesity and rheumatology in the Nordic Region. In 1991 she joined the Department of Cardiovascular Development in Basel, Switzerland. Her first project was to be clinically responsible for the NDA filing in the European Union of a fixed combination of the ACE-inhibitor cilazapril and hydrochlorothiazide. She then joined the team that developed mibefradil, a calcium antagonist, for the indications hypertension, angina pectoris and congestive heart failure. In 1998 she joined Pharmacia in Stockholm where she was the global medical director for urology and sexual dysfunction. She was responsible for the filing of 2 NDAs, Caverject® Dual Chamber and tolterodine (Detrusitol®/Detrol®) prolonged release. In 2002 she joined AstraZeneca as a senior research physician initially working on a CINOD (NSAID+NO) project. Upon completion of that project she worked on a thrombin inhibitor (Exanta®) project during the global regulatory review.
In 2005 she joined Actelion in Allschwil Switzerland, where she was Therapeutic Area Head responsible for several pulmonary/cardiovascular projects (i.e. selexipag, tezosentan, iloprost, epoprostenol).
She left Actelion in 2012 and joined Axicos in Basel, Switzerland, building up the strategic drug development group. She joined Metys Pharmaceuticals in 2014 as consulting Chief Medical Officer.